• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服耐受的动力学分析:记忆淋巴细胞对口服耐受具有抗性。

Kinetic analysis of oral tolerance: memory lymphocytes are refractory to oral tolerance.

作者信息

Chung Y, Chang S Y, Kang C Y

机构信息

Laboratory of Immunology, College of Pharmacy, Seoul National University, Korea.

出版信息

J Immunol. 1999 Oct 1;163(7):3692-8.

PMID:10490964
Abstract

Oral administration of soluble Ag before immunization induces peripheral tolerance and is effective in suppressing animal models of autoimmune diseases. Although tolerance induction in primed animals is more clinically relevant, it is not well studied. Therefore, this study was designed to examine the feeding effects on different phases of the immune response. We observed that feeding a single high dose (250 mg) of OVA to OVA-primed BALB/c mice could induce OVA-specific suppression in the Ab production and T cell proliferation only at the naive and the activation phases of the immune response, whereas multiple high doses (100 mg/feed for 10 days) were effective at the effector phase. OVA-specific IL-4 production in culture supernatant was also suppressed in the tolerized groups. However, when the mice had resting memory lymphocytes, even multiple feeding regimens were not effective in tolerance induction, although multiple low doses (1 mg/feed for 10 days) partially suppressed Ab production. This phenomenon was confirmed by adoptive transfer study. Nevertheless, the reactivated memory response was suppressed partially by multiple high doses. Our findings have an important implication for understanding the mechanism of oral tolerance and for the therapeutic applications of oral tolerance to autoimmune diseases.

摘要

免疫前口服可溶性抗原可诱导外周耐受,并有效抑制自身免疫性疾病的动物模型。虽然在已致敏动物中诱导耐受在临床上更具相关性,但对此研究较少。因此,本研究旨在考察喂食对免疫反应不同阶段的影响。我们观察到,给已用卵清蛋白(OVA)致敏的BALB/c小鼠单次喂食高剂量(250毫克)OVA,仅在免疫反应的初始和激活阶段可诱导OVA特异性抑制抗体产生和T细胞增殖,而多次高剂量(每次100毫克,共喂食10天)在效应阶段有效。耐受组培养上清中OVA特异性白细胞介素-4的产生也受到抑制。然而,当小鼠具有静息记忆淋巴细胞时,即使多次喂食方案也无法有效诱导耐受,尽管多次低剂量(每次1毫克,共喂食10天)可部分抑制抗体产生。过继转移研究证实了这一现象。尽管如此,多次高剂量可部分抑制重新激活的记忆反应。我们的研究结果对于理解口服耐受机制以及口服耐受在自身免疫性疾病治疗中的应用具有重要意义。

相似文献

1
Kinetic analysis of oral tolerance: memory lymphocytes are refractory to oral tolerance.口服耐受的动力学分析:记忆淋巴细胞对口服耐受具有抗性。
J Immunol. 1999 Oct 1;163(7):3692-8.
2
Priming or tolerization of the B- and Th2-dependent immune response by the oral administration of OVA-DNP is determined by the antigen dosage.通过口服卵清蛋白-二硝基苯(OVA-DNP)引发或诱导B细胞和Th2细胞依赖性免疫反应取决于抗原剂量。
Cell Immunol. 1998 Nov 25;190(1):1-11. doi: 10.1006/cimm.1998.1356.
3
Induction of oral tolerance in the primed immune system: influence of antigen persistence and adjuvant form.致敏免疫系统中口服耐受的诱导:抗原持续性和佐剂形式的影响。
Cell Immunol. 2000 Jun 15;202(2):71-8. doi: 10.1006/cimm.2000.1665.
4
Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin.通过口服分泌卵清蛋白的乳酸乳球菌诱导卵清蛋白特异性耐受。
Gastroenterology. 2007 Aug;133(2):517-28. doi: 10.1053/j.gastro.2007.04.073. Epub 2007 May 3.
5
The kinetics of oral hyposensitization to a protein antigen are determined by immune status and the timing, dose and frequency of antigen administration.口服蛋白质抗原减敏疗法的动力学取决于免疫状态以及抗原给药的时间、剂量和频率。
Immunology. 1989 Jul;67(3):425-30.
6
In vivo tolerization of Th1 lymphocytes following a single feeding with ovalbumin: anergy in the absence of suppression.用卵清蛋白单次喂食后Th1淋巴细胞的体内耐受:无抑制情况下的无反应性
Eur J Immunol. 1994 Sep;24(9):1974-81. doi: 10.1002/eji.1830240906.
7
Intranasal treatment with ovalbumin but not the major T cell epitope ovalbumin 323-339 generates interleukin-10 secreting T cells and results in the induction of allergen systemic tolerance.用卵清蛋白而非主要T细胞表位卵清蛋白323 - 339进行鼻内治疗可产生分泌白细胞介素-10的T细胞,并导致变应原全身耐受性的诱导。
Clin Exp Allergy. 2004 Apr;34(4):654-62. doi: 10.1111/j.1365-2222.2004.1929.x.
8
Direct evidence for anergy in T lymphocytes tolerized by oral administration of ovalbumin.经口服卵清蛋白诱导耐受的T淋巴细胞无反应性的直接证据。
Eur J Immunol. 1993 Apr;23(4):935-42. doi: 10.1002/eji.1830230426.
9
Abrogation of oral tolerance by feeding encapsulated antigen.
Cell Immunol. 2000 Feb 1;199(2):65-72. doi: 10.1006/cimm.1999.1603.
10
Complementary role of CD4+CD25+ regulatory T cells and TGF-beta in oral tolerance.CD4+CD25+调节性T细胞与转化生长因子-β在口服耐受中的互补作用。
J Leukoc Biol. 2005 Jun;77(6):906-13. doi: 10.1189/jlb.1004599. Epub 2005 Mar 9.

引用本文的文献

1
APC-targeted proinsulin expression inactivates insulin-specific memory CD8 T cells in NOD mice.APC 靶向的胰岛素原表达使 NOD 小鼠的胰岛素特异性记忆 CD8 T 细胞失活。
Immunol Cell Biol. 2017 Oct;95(9):765-774. doi: 10.1038/icb.2017.48. Epub 2017 Jun 14.
2
Oral-tolerization Prevents Immune Responses and Improves Transgene Persistence Following Gene Transfer Mediated by Adeno-associated Viral Vector.口服耐受可预防免疫反应并改善腺相关病毒载体介导的基因转移后的转基因持久性。
Mol Ther. 2016 Feb;24(1):87-95. doi: 10.1038/mt.2015.146. Epub 2015 Aug 12.
3
Active suppression induced by repetitive self-epitopes protects against EAE development.
重复自身表位诱导的主动抑制可预防 EAE 的发展。
PLoS One. 2013 May 30;8(5):e64888. doi: 10.1371/journal.pone.0064888. Print 2013.
4
Oral tolerance in T cells is accompanied by induction of effector function in lymphoid organs after systemic immunization.T细胞中的口服耐受性伴随着全身免疫后淋巴器官中效应功能的诱导。
Infect Immun. 2004 Jul;72(7):3803-11. doi: 10.1128/IAI.72.7.3803-3811.2004.
5
Co-administration of CD40 agonistic antibody and antigen fails to overcome the induction of oral tolerance.共给予CD40激动性抗体和抗原无法克服口服耐受的诱导。
Immunology. 2004 Jan;111(1):19-26. doi: 10.1111/j.1365-2567.2004.01787.x.
6
Induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice.用重组橡胶树巴西橡胶蛋白1和重组橡胶树巴西橡胶蛋白3诱导黏膜耐受以预防BALB/c小鼠的乳胶过敏
Clin Exp Immunol. 2003 Aug;133(2):170-6. doi: 10.1046/j.1365-2249.2003.02210.x.
7
Oral tolerance of food.食物的口服耐受性。
Curr Allergy Asthma Rep. 2002 Jan;2(1):73-7. doi: 10.1007/s11882-002-0043-9.